Compare Phillips 66 (PSX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Regeneron Pharmaceuticals Inc — how do they compare? Phillips 66 trades at $281 (market cap $108.38B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Phillips 66 is the larger of the two by market cap, and Phillips 66 pays the higher dividend (1.87%). Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PSX | REGN | |
|---|---|---|
Market Cap | $108.38B | $76.40B |
Volume | 1,841,742 | 626,381 |
Sector | Energy | Health |
52-Week High | $281.60 | $852.03 |
52-Week Low | $126.76 | $557.73 |
Typical Hold Time | 62 Days | 107 Days |
Enterprise Value | $124.85B | $71.12B |
Dividend Yield | 1.87% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSX trades at $281.60, up 4.38% today, near its 52-week high. The stock shows bullish technical momentum with strong moving average support. Fundamentally, the company has beaten earnings estimates for three consecutive quarters, with a P/E of 15.5 and robust ROE of 24.02%. Recent news highlights structural strength in refining margins and AI-driven operational improvements.
Outlook remains positive with analyst consensus at Buy (57% of ratings) and a $279 price target. Key opportunities include sustained refining profitability and debt reduction. Risks involve volatile energy markets and potential policy impacts on diesel exports. Cash flow is projected to rebound to $3.0B in 2026.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
